Opis działalności
Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, and AMVUTTRA® (vutrisiran) in 2022. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Zarząd & Rada nadzorcza
| CEO |
| Yvonne Greenstreet |
| Zarząd |
| Jeff Poulton, Akshay Vaishnaw, Pushkal Garg, Kelley Boucher, Tim Maines, Tolga Tanguler, Indrani Franchini, Piyush Sharma, Evan Lippman, Kevin Fitzgerald |
| Rada nadzorcza |
| Amy W. Schulman, Dennis A. Ausiello, Carolyn Bertozzi, Michael W. Bonney, Olivier Brandicourt, Marsha H. Fanucci, Yvonne Greenstreet, Margaret A. Hamburg, Peter N. Kellogg, David E.I. Pyott, Colleen F. Reitan, Phillip A. Sharp, Elliott Sigal |
Dane firmy
| Nazwa: |
Alnylam Pharmaceuticals, Inc |
| Adres: |
675 West Kendall St,Cambridge, MA 02142 |
| Telefon: |
+1 617-551-8200 |
| Fax: |
+1 617-551-8101 |
| E-mail: |
INFO@ALNYLAM.COM
|
| Internet: |
https://www.alnylam.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
- |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
01.05.2004 |
